Canaccord morning comment from Growth conferenceProMetic Life Sciences (PLI:TSX, C$2.78 | BUY, C$4.50 target) Although we think that expectations are high for upcoming Phase III results, we expect that near-term catalysts for plasminogen include the filing of the BLA and a potential Priority Review. This should focus investor attention on the likely near-term commercialization of ProMetics first big product. Moreover, PBI-4050 has already demonstrated efficacy in a Phase II study in diabetes, and we believe upcoming data from a Phase II in Alstrom syndrome should provide clear validation of this drug in a very difficult and rare disease. At the end of the day, we believe ProMetic is a manufacturing story. The technology has been validated many times over by big pharma partners and the FDA has supported the regulatory path for its lead products, which suggests much lower risk and shorter timelines for development.